To animate the Banner

Picture Name

Apply for post


Recruitment Position

Place of work

Number of Recruits

Salary Treatment

ICP-B02

ICP-B02(CM355) is a CD3xCD20 bispecific antibody developed. ICP-B02 specifically binds to CD20 positive target cells and CD3 positive T cells, recruits immune T cells to the periphery of target cells, activates T cells, and induces T cell-mediated tumor cell killing (TDCC) to kill target cells for the treatment of CD20 + B cell hematoma. Preliminary data show that ICP-B02 intravenous (IV) and subcutaneous (SC) formulations have demonstrated good efficacy in both follicular lymphoma (FL) and diffuse large B- cell lymphoma (DLBCL) patients. Among the 13 patients who received at least one dose of 6 mg or more, the overall response rate (ORR) was 100 percent. Non-Hodgkin's lymphoma (NHL) is the main type of CD20 + B- cell hematoma, accounting for 80%-90% of B- cell lymphomas, including diffuse large B- cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), etc.

Gender
Marriage
kg
cm
Please upload a resume file smaller than 5M ~